Delandistrogene Moxeparvovec基因治疗行走能力尚存的≥4至<8岁杜氏肌营养不良患者:研究SRP-9001-103(ENDEAVOR)的1年期中结果
ENDEAVOR(SRP-9001-103;NCT04626674)是一项单臂、开放标签研究,纳入20例≥4至<8岁可行走的男性杜氏肌营养不良患者,单次静脉输注delandistrogene moxeparvovec(1.33×10^14 vg/kg)。第12周西方印迹法检测的微肌营养不良蛋白较基线变化均值为54.2%(标准差42.6),p<0.0001;1年时北极星步行评估总分较基线变化均值为+4.0(标准差3.5),与倾向评分加权的外部自然史对照相比,最小二乘均值差异为+3.2(标准误0.6)分,p<0.0001。治疗总体耐受良好,运动功能稳定或改善,提示临床获益。
要点
- 单次静脉输注delandistrogene moxeparvovec(1.33×10^14 vg/kg)后第12周微肌营养不良蛋白较基线变化均值为54.2%(标准差42.6),p<0.0001。
- 1年时北极星步行评估总分较基线变化均值为+4.0(标准差3.5),与倾向评分加权外部对照相比最小二乘均值差异为+3.2(标准误0.6)分,p<0.0001。
- 1年安全性特征与其他delandistrogene moxeparvovec试验(NCT03375164和NCT03769116)报告的安全性数据一致。
核心结论
- 结果证实delandistrogene moxeparvovec可有效转导肌肉;治疗1年后耐受良好,运动功能稳定或改善,提示对杜氏肌营养不良患者有临床获益。
研究设计与样本
- ENDEAVOR(SRP-9001-103;NCT04626674)为单臂、开放标签研究,队列1纳入20例≥4至<8岁可行走的男性杜氏肌营养不良患者,单次静脉输注delandistrogene moxeparvovec(1.33×10^14 vg/kg)。
主要发现
- 第12周西方印迹法检测的微肌营养不良蛋白较基线变化均值为54.2%(标准差42.6),p<0.0001,免疫荧光显示肌膜定位。
- 1年时北极星步行评估总分较基线变化均值为+4.0(标准差3.5),患者表现为稳定或改善。
- 与倾向评分加权的外部自然史对照相比,北极星步行评估总分较基线变化的最小二乘均值差异为+3.2(标准误0.6)分,p<0.0001。
- 1年安全性特征与其他delandistrogene moxeparvovec试验(NCT03375164和NCT03769116)报告的安全性数据一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Delandistrogene moxeparvovec is approved in the USA for the treatment of ambulatory patients (4-5 years) with Duchenne muscular dystrophy. ENDEAVOR (SRP-9001-103; NCT04626674) is a single-arm, open-label study to evaluate delandistrogene moxeparvovec micro-dystrophin expression, safety, and functional outcomes following administration of commercial process delandistrogene moxeparvovec. METHODS: In cohort 1 of ENDEAVOR (N = 20), eligible ambulatory males, aged ≥4 to <8 years, received a single intravenous infusion of delandistrogene moxeparvovec (1.33 × 1014 vg/kg). The primary endpoint was change from baseline (CFBL) to week 12 in delandistrogene moxeparvovec micro-dystrophin by western blot. Additional endpoints evaluated included: safety; vector genome copies; CFBL to week 12 in muscle fiber-localized micro-dystrophin by immunofluorescence; and functional assessments, including North Star Ambulatory Assessment, with comparison with a propensity score-weighted external natural history control. RESULTS: The 1-year safety profile of commercial process delandistrogene moxeparvovec in ENDEAVOR was consistent with safety data reported in other delandistrogene moxeparvovec trials (NCT03375164 and NCT03769116). Delandistrogene moxeparvovec micro-dystrophin expression was robust, with sarcolemmal localization at week 12; mean (SD) CFBL in western blot, 54.2% (42.6); p < 0.0001. At 1 year, patients demonstrated stabilized or improved North Star Ambulatory Assessment total scores; mean (SD) CFBL, +4.0 (3.5). Treatment versus a propensity score-weighted external natural history control demonstrated a statistically significant difference in least squares mean (standard error) CFBL in North Star Ambulatory Assessment, +3.2 (0.6) points; p < 0.0001. INTERPRETATION: Results confirm efficient transduction of muscle by delandistrogene moxeparvovec. One-year post-treatment, delandistrogene moxeparvovec was well tolerated, and demonstrated stabilized or improved motor function, suggesting a clinical benefit for patients with Duchenne muscular dystrophy. ANN NEUROL 2023;94:955-968.
引用
- Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023. PMID: 37539981. doi:10.1002/ana.26755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。